| 臺大學術典藏 |
2021-02-23T08:26:32Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H. ;Kuo Y.-H. ;Tien Y.-W. ;Hsu C. ;Hsu C.-H. ;Sung-Hsin Kuo ;Cheng A.-L.; Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; SUNG-HSIN KUO; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:32Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Sung-Hsin Kuo ;Cheng A.-L. ;Lin C.-W. ;Hsu C.-H. ;Wu M.-S. ;Yeh K.-H. ;Tzeng Y.-S. ;Chen L.-T.; SUNG-HSIN KUO; Cheng A.-L.; Lin C.-W.; Hsu C.-H.; Wu M.-S.; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-23T08:26:28Z |
Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-�eb is associated with a poor prognosis of pancreatic cancer
|
Yang S.-H.;Hsu C.-H.;Lee J.-C.;Tien Y.-W.;Sung-Hsin Kuo;Cheng A.-L.; Yang S.-H.; Hsu C.-H.; Lee J.-C.; Tien Y.-W.; SUNG-HSIN KUO; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:21Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-02-04T02:30:20Z |
The preparation of cell-containing microbubble scaffolds to mimic alveoli structure as a 3D drug-screening system for lung cancer
|
Sun, Y.-J.;Hsu, C.-H.;Ling, T.-Y.;Liu, L.;Lin, T.-C.;Jakfar, S.;Young, I.-C.;Lin, F.-H.Feng-Huei Lin; Sun, Y.-J.; Hsu, C.-H.; Ling, T.-Y.; Liu, L.; Lin, T.-C.; Jakfar, S.; Young, I.-C.; Lin, F.-H.; FENG-HUEI LIN |
| 臺大學術典藏 |
2021-02-04T02:29:43Z |
Process integration of E-waste carbonization and High-gravity rotating packed bed for optimal gold recovery and the fine particles reduction
|
Huynh, G.-H.;Chen, T.-L.;Hsu, C.-H.;Chen, Y.-H.;Chiang, P.-C.; Huynh, G.-H.; Chen, T.-L.; Hsu, C.-H.; Chen, Y.-H.; Chiang, P.-C.; PEN-CHI CHIANG |
| 臺大學術典藏 |
2021-02-03T05:42:26Z |
Esophageal adenocarcinoma arising from Barrett's epithelium in Taiwan
|
CHIA-HUNG TU; Lee C.-T.; Perng D.-S.; Chang C.-C.; Hsu C.-H.; Lee Y.-C. |
| 臺大學術典藏 |
2021-02-02T08:29:56Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; BOR-RU LIN; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T05:45:47Z |
Esophageal adenocarcinoma arising from Barrett's epithelium in Taiwan
|
Tu C.-H.;Lee C.-T.;Perng D.-S.;Chang C.-C.;Hsu C.-H.;Yi-Chia Lee; Tu C.-H.; Lee C.-T.; Perng D.-S.; Chang C.-C.; Hsu C.-H.; YI-CHIA LEE |
| 臺大學術典藏 |
2021-02-02T02:22:37Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:21:42Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H.; Cheng A.-L.; Lin C.-W.; Hsu C.-H.; MING-SHIANG WU; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Yeong-Shiau Pu;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y.; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; YEONG-SHIAU PU; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Lin C.-C.;Hsu C.-H.;Chen J.;Tsai T.-C.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Chen J.; Tsai T.-C.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma
|
Hsu C.-H.;Chen J.;Wu C.-Y.;Cheng A.-L.;Yeong-Shiau Pu; Hsu C.-H.; Chen J.; Wu C.-Y.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:47:00Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Cheng A.-L.;Chen J.;Vogelzang N.J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Chen J.; Vogelzang N.J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:47:00Z |
Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study
|
Lin C.-C.;Hsu C.-H.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:59Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Cheng A.-L.;Vogelzang N.J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Vogelzang N.J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.;Hsu C.-H.;Hour T.-C.;Cheng A.-L.;Huang C.-Y.;Huang K.-H.;Chen J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Hour T.-C.; Cheng A.-L.; Huang C.-Y.; Huang K.-H.; Chen J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:53Z |
Systemic therapy for metastatic urothelial carcinoma
|
Lin C.-C.; Hsu C.-H.; YEONG-SHIAU PU; Vogelzang N.J. |
| 臺大學術典藏 |
2021-02-02T00:46:51Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Lin C.-C.; YEONG-SHIAU PU; Hsu C.-H.; Keng H.-Y.; Cheng A.-L.; Yang C.-H. |
| 臺大學術典藏 |
2021-02-02T00:46:47Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:29Z |
Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells
|
Huang K.-H.; Kuo K.-L.; Ho I.-L.; Chang H.-C.; Chuang Y.-T.; Lin W.-C.; Lee P.-Y.; Chang S.-C.; Chiang C.-K.; YEONG-SHIAU PU; Chou C.-T.; Hsu C.-H.; Liu S.-H. |
| 臺大學術典藏 |
2021-02-02T00:46:21Z |
MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies
|
Kuo K.-L.;Ho I.-L.;Shi C.-S.;Wu J.-T.;Lin W.-C.;Tsai Y.-C.;Chang H.-C.;Chou C.-T.;Hsu C.-H.;Hsieh J.-T.;Chang S.-C.;Yeong-Shiau Pu;Huang K.-H.; Kuo K.-L.; Ho I.-L.; Shi C.-S.; Wu J.-T.; Lin W.-C.; Tsai Y.-C.; Chang H.-C.; Chou C.-T.; Hsu C.-H.; Hsieh J.-T.; Chang S.-C.; YEONG-SHIAU PU; Huang K.-H. |
